Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells $1,500,780.00 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 6,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $250.13, for a total transaction of $1,500,780.00. Following the completion of the sale, the director directly owned 351,875 shares in the company, valued at $88,014,493.75. This represents a 1.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $246.81 on Friday. Jazz Pharmaceuticals PLC has a 1 year low of $123.88 and a 1 year high of $266.38. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.58 and a current ratio of 1.78. The firm has a 50 day moving average price of $249.14 and a 200 day moving average price of $221.14. The company has a market cap of $16.02 billion, a price-to-earnings ratio of 17.02, a PEG ratio of 0.22 and a beta of 0.36.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing analysts’ consensus estimates of $6.18 by ($0.47). Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%.The company had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.11 billion. During the same period in the prior year, the business earned ($8.25) EPS. The business’s revenue for the quarter was up 15.5% on a year-over-year basis. Sell-side analysts predict that Jazz Pharmaceuticals PLC will post 21.5 earnings per share for the current year.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. USA Financial Formulas acquired a new stake in Jazz Pharmaceuticals in the first quarter valued at approximately $25,000. Ameritas Advisory Services LLC purchased a new stake in Jazz Pharmaceuticals during the 2nd quarter worth approximately $47,000. LRI Investments LLC acquired a new position in shares of Jazz Pharmaceuticals in the 4th quarter valued at approximately $38,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Jazz Pharmaceuticals in the 2nd quarter valued at approximately $61,000. Finally, Westpac Banking Corp purchased a new position in shares of Jazz Pharmaceuticals during the 1st quarter valued at approximately $51,000. 89.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

JAZZ has been the subject of a number of research reports. Sanford C. Bernstein reissued a “market perform” rating on shares of Jazz Pharmaceuticals in a research report on Tuesday, June 9th. Needham & Company LLC boosted their target price on Jazz Pharmaceuticals from $292.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, August 26th. Wells Fargo & Company raised their price target on shares of Jazz Pharmaceuticals from $285.00 to $300.00 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Weiss Ratings raised shares of Jazz Pharmaceuticals from a “hold (c-)” rating to a “buy (b-)” rating in a research report on Tuesday, August 4th. Finally, Royal Bank Of Canada set a $299.00 price objective on shares of Jazz Pharmaceuticals in a research note on Friday, August 28th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $285.44.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.